GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (OTCPK:HMTXF) » Definitions » Liabilities-to-Assets

HMTXF (Hemostemix) Liabilities-to-Assets : 55.69 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Hemostemix Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Hemostemix's Total Liabilities for the quarter that ended in Sep. 2024 was $6.52 Mil. Hemostemix's Total Assets for the quarter that ended in Sep. 2024 was $0.12 Mil. Therefore, Hemostemix's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2024 was 55.69.


Hemostemix Liabilities-to-Assets Historical Data

The historical data trend for Hemostemix's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemostemix Liabilities-to-Assets Chart

Hemostemix Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.89 1.47 10.38 15.57 24.48

Hemostemix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.53 10.78 24.48 35.26 55.69

Competitive Comparison of Hemostemix's Liabilities-to-Assets

For the Biotechnology subindustry, Hemostemix's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemostemix's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemostemix's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Hemostemix's Liabilities-to-Assets falls into.


;
;

Hemostemix Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Hemostemix's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=5.728/0.234
=24.48

Hemostemix's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2024 is calculated as

Liabilities-to-Assets (Q: Sep. 2024 )=Total Liabilities/Total Assets
=6.516/0.117
=55.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hemostemix  (OTCPK:HMTXF) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Hemostemix Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Hemostemix's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemostemix Business Description

Traded in Other Exchanges
Address
707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.